HomeAI · summaries
Storia in 2 fonti
Evolocumab before PCI for acute MI improves LDL control
MUNICH — Early administration of evolocumab prior to PCI for acute MI significantly improved patients’ chances of meeting guideline-recommended LDL goals by 1 year, but did not impact clinical outcomes vs. standard care.Fewer patients who received standard care alone achieved LDL control at 1 year compared with those who initiated evolocumab (Repatha, Amgen) prior to PCI on top of
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Evolocumab before PCI for acute MI improves LDL control
MUNICH — Early administration of evolocumab prior to PCI for acute MI significantly improved patients’ chances of meeting guideline-recommended LDL goals by 1 year, but did not…
- ·
medpagetoday.com
Rush to PCSK9 Inhibitor Pretreatment Disappoints in Acute MI Trial
Quick lipid lowering did not translate to clinical benefit at 1 year